Evidence map›Paper›PMID 40730154›Full record

ArticleCell2025

Cancer immunology data engine reveals secreted AOAH as a potential immunotherapy.

Lanqi Gong, Jie Luo, Emily Yang, Beibei Ru, Ziyang Qi, Yuma Yang, Anshu Rani, Abhilasha Purohit, Yu Zhang, Grace Guan and 13 more

Abstract read
In one paragraph

Article in Cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Lanqi GongCancer Data Science Lab, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Jie LuoDepartment of Clinical Oncology, The University of Hong Kong (HKU), Hong Kong, China.
Emily YangCancer Data Science Lab, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Beibei RuCancer Data Science Lab, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Ziyang QiDepartment of Clinical Oncology, The University of Hong Kong (HKU), Hong Kong, China.
Yuma YangDepartment of Clinical Oncology, The University of Hong Kong (HKU), Hong Kong, China.
Anshu RaniCancer Data Science Lab, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Abhilasha PurohitCancer Data Science Lab, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Yu ZhangState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Grace GuanCancer Data Science Lab, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Rohit PaulOffice of the Director, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Trang VuCancer Data Science Lab, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Zuojia ChenExperimental Immunology Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Renyue JiSchool of Public Health, HKU, Hong Kong, China.
Chi-Ping DayCancer Data Science Lab, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Chuan WuExperimental Immunology Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Glenn MerlinoLaboratory of Cancer Biology and Genetics, CCR, NCI, NIH, Bethesda, MD 20892, USA.
David FitzgeraldLaboratory of Molecular Biology, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Grégoire Altan-BonnetLaboratory of Integrative Cancer Immunology, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Kenneth AldapeLaboratory of Pathology, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Jiansheng WuWuXi Biologics, 7 Clark Drive, Cranbury, NJ 08512, USA.
Xinyuan GuanDepartment of Clinical Oncology, The University of Hong Kong (HKU), Hong Kong, China. Electronic address: xyguan@hku.hk.
Peng JiangCancer Data Science Lab, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA. Electronic address: peng.jiang@nih.gov.

Funding

Data-driven inference of regulators for cytokine-mediated tumor killingZIABC011889 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JIANG, PENG · 2019 to 2025
$4.1M
T cell regulation for intestinal barrier functionZIABC011801 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WU, CHUAN · 2018 to 2025
$4.1M
Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC011801Intramural NIH HHS ZIA BC011889
6 · The paper itself

Abstract

Secreted proteins are central mediators of intercellular communications and can serve as therapeutic targets in diverse diseases. The ∼1,903 human genes encoding secreted proteins are difficult to study through common genetic approaches. To address this hurdle and, more generally, to discover cancer therapeutics, we developed the Cancer Immunology Data Engine (CIDE, https://cide.ccr.cancer.gov), which incorporates 90 omics datasets spanning 8,575 tumor profiles with immunotherapy outcomes from 17 solid tumor types. CIDE systematically identifies all genes associated with immunotherapy outcomes. Then, we focused on secreted proteins prioritized by CIDE without known cancer roles and validated regulatory effects on immune checkpoint blockade for AOAH, CR1L, COLQ, and ADAMTS7 in mouse models. The top hit, acyloxyacyl hydrolase (AOAH), potentiates immunotherapies in multiple tumor models by sensitizing T cell receptors to weak antigens and protecting dendritic cells through depleting immunosuppressive arachidonoyl phosphatidylcholines and oxidized derivatives.

Indexed as

ImmunotherapyNeoplasmsAnimalsDendritic CellsHumansImmune Checkpoint InhibitorsMiceImmune Checkpoint Inhibitorsacyloxyacyl hydrolaseADAMTS7AOAHarachidonoyl phosphatidylcholinecancer immunotherapyCOLQCR1Ldatabaseoxidized phospholipidsecreted protein

Identifiers

PMID40730154
PMCPMC12434699

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.